Efficacy and Safety of Edifoligide, an E2F Transcription Factor Decoy, for Prevention of Vein Graft Failure Following Coronary Artery Bypass Graft Surgery: PREVENT IV: A Randomized Controlled Trial

医学 外科 临床终点 动脉 新生内膜增生 静脉 心脏病学 狭窄 冠状动脉搭桥手术 安慰剂 狼牙棒 再狭窄 内科学 心肌梗塞 随机对照试验 经皮冠状动脉介入治疗 支架 病理 替代医学
作者
PREVENT IV Investigators*
出处
期刊:JAMA [American Medical Association]
卷期号:294 (19): 2446-2446 被引量:689
标识
DOI:10.1001/jama.294.19.2446
摘要

CONTEXT: Coronary artery bypass graft (CABG) surgery with autologous vein grafting is commonly performed. Progressive neointimal hyperplasia, however, contributes to considerable vein graft failure. Edifoligide is an oligonucleotide decoy that binds to and inhibits E2F transcription factors and thus may prevent neointimal hyperplasia and vein graft failure. OBJECTIVE: To assess the efficacy and safety of pretreating vein grafts with edifoligide for patients undergoing CABG surgery. DESIGN, SETTING, AND PARTICIPANTS: A phase 3 randomized, double-blind, placebo-controlled trial of 3014 patients undergoing primary CABG surgery with at least 2 planned saphenous vein grafts and without concomitant valve surgery, who were enrolled between August 2002 and October 2003 at 107 US sites. INTERVENTION: Vein grafts were treated ex vivo with either edifoligide or placebo in a pressure-mediated delivery system. The first 2400 patients enrolled were scheduled for 12- to 18-month follow-up angiography. MAIN OUTCOME MEASURES: The primary efficacy end point was angiographic vein graft failure (> or =75% vein graft stenosis) occurring 12 to 18 months after CABG surgery. Other end points included other angiographic variables, adverse events through 30 days, and major adverse cardiac events. RESULTS: A total of 1920 patients (80%) either died (n = 91) or underwent follow-up angiography (n = 1829). Edifoligide had no effect on the primary end point of per patient vein graft failure (436 [45.2%] of 965 patients in the edifoligide group vs 442 [46.3%] of 955 patients in the placebo group; odds ratio, 0.96 [95% confidence interval {CI}, 0.80-1.14]; P = .66), on any secondary angiographic end point, or on the incidence of major adverse cardiac events at 1 year (101 [6.7%] of 1508 patients in the edifoligide group vs 121 [8.1%] of 1506 patients in the placebo group; hazard ratio, 0.83 [95% CI, 0.64-1.08]; P = .16). CONCLUSIONS: Failure of at least 1 vein graft is quite common within 12 to 18 months after CABG surgery. Edifoligide is no more effective than placebo in preventing these events. Longer-term follow-up and additional research are needed to determine whether edifoligide has delayed beneficial effects, to understand the mechanisms and clinical consequences of vein graft failure, and to improve the durability of CABG surgery. Clinical Trial Registration ClinicalTrials.gov Identifier: NCT00042081.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
jing发布了新的文献求助10
4秒前
可爱的函函的应助被liuliu采纳,获得10
4秒前
慕青的应助被liuliu采纳,获得10
4秒前
4秒前
4秒前
巨小俊发布了新的文献求助10
5秒前
在水一方的应助被Brufo采纳,获得20
6秒前
白华苍松发布了新的文献求助20
6秒前
LeslieWu完成签到,获得积分10
7秒前
7秒前
Nole的应助被喬老師采纳,获得10
8秒前
刘清发布了新的文献求助10
9秒前
9秒前
鸣熠完成签到,获得积分10
10秒前
香蕉觅云的应助被谢富杰采纳,获得10
12秒前
12秒前
可可完成签到 ,获得积分10
12秒前
CipherSage的应助被muderder采纳,获得10
12秒前
13秒前
轻松峻熙发布了新的文献求助10
14秒前
科研通AI6.4的应助被ygy采纳,获得10
14秒前
贾贡献的应助被十二采纳,获得10
14秒前
迟宏珈发布了新的文献求助10
16秒前
文静迎南发布了新的文献求助10
17秒前
17秒前
17秒前
18秒前
CipherSage的应助被hyska采纳,获得10
18秒前
陈红安完成签到,获得积分10
19秒前
19秒前
巨小俊完成签到,获得积分10
20秒前
WT发布了新的文献求助10
21秒前
道天完成签到,获得积分10
22秒前
轻松峻熙完成签到,获得积分10
23秒前
谢富杰发布了新的文献求助10
23秒前
jiashan发布了新的文献求助30
23秒前
xh发布了新的文献求助10
24秒前
LeeStrife完成签到 ,获得积分10
24秒前
25秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188394
求助须知:如何正确求助?哪些是违规求助? 9576268
关于积分的说明 21846207
捐赠科研通 7786486
什么是DOI,文献DOI怎么找? 3435317
关于科研通互助平台的介绍 2559618
邀请新用户注册赠送积分活动 2482322